T1	Participants 170 190	survival of patients
T2	Participants 275 297	paclitaxel in patients
T3	Participants 408 472	Patients with bidimensionally measurable disease were randomised
T4	Participants 580 602	Patients were eligible
T5	Participants 946 969	A total of 226 patients
T6	Participants 1679 1742	Non-haematological toxicity was generally mild for both groups.
T7	Participants 1817 1859	this group of patients receiving topotecan
